[177Lu]DOTA-anti-CD20: labeling and pre-clinical studies

Paola F Audicio; Gustavo Castellano; Marcos R Tassano; Maria E Rezzano; Marcelo Fernandez; Eloisa Riva; Ana Robles; Pablo Cabral; Henia Balter; Patricia Oliver

doi:10.1016/j.apradiso.2011.01.026

[177Lu]DOTA-anti-CD20: labeling and pre-clinical studies

Appl Radiat Isot. 2011 Jul;69(7):924-8. doi: 10.1016/j.apradiso.2011.01.026. Epub 2011 Jan 26.

Authors

Paola F Audicio¹, Gustavo Castellano, Marcos R Tassano, Maria E Rezzano, Marcelo Fernandez, Eloisa Riva, Ana Robles, Pablo Cabral, Henia Balter, Patricia Oliver

Affiliation

¹ Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo, Uruguay. [email protected]

PMID: 21474325
DOI: 10.1016/j.apradiso.2011.01.026

Abstract

Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin's Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with (177)Lu through a simple method. [(177)Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. Monte Carlo simulation showed high doses deposited on a spheroid tumor mass model. This method seems to be an appropriate alternative for the production of [(177)Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Male
Mice
Monte Carlo Method
Radiopharmaceuticals / administration & dosage*
Radiopharmaceuticals / chemistry
Radiopharmaceuticals / pharmacokinetics
Tissue Distribution

Substances

Radiopharmaceuticals